Related Experiment Video
Updated: Sep 19, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
83.9K
Factor XI inhibitors: is it time for a paradigm shift in anticoagulation?
Paolo Ossola1, Claudio Ciampi1, Andrea Cesari2
1Health Science Department, University of Milan Bicocca.
Journal of Cardiovascular Medicine (Hagerstown, Md.)
|June 5, 2025
Summary
Factor XI (FXI) inhibitors offer new anticoagulation strategies with potential benefits for reducing thrombosis and bleeding. Research is exploring molecules, antibodies, and oligonucleotides for FXI inhibition.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Factor XI (FXI) plays a crucial role in the coagulation cascade, linking intrinsic and common pathways.
- Understanding thrombosis has driven the development of targeted anticoagulant therapies.
- FXI inhibitors are emerging as promising therapeutic agents.
Purpose of the Study:
- To review the latest advancements in Factor XI (FXI) inhibitors as novel anticoagulation strategies.
- To analyze the potential advantages of FXI inhibition over existing anticoagulants.
- To discuss the discovery and application of molecules, antibodies, and antisense oligonucleotides targeting FXI.
Main Methods:
- Literature review of recent clinical trials and research on FXI inhibitors.
- Analysis of biochemical and pharmacological data related to FXI binding agents.
- Synthesis of information on novel anticoagulation strategies targeting FXI.
Main Results:
- FXI inhibitors demonstrate potential for reduced thrombotic risk.
- These inhibitors may offer improved safety profiles with limited bleeding complications.
- Various therapeutic modalities, including small molecules, antibodies, and antisense oligonucleotides, are being investigated.
Conclusions:
- Factor XI (FXI) inhibition represents a significant advancement in anticoagulation therapy.
- Targeting FXI offers a promising approach to balance antithrombotic efficacy and safety.
- Ongoing research and clinical trials are paving the way for new anticoagulation strategies.
More Related Videos
06:16Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
Published on: April 19, 2024
1.2K
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
13.9K
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
932
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
932
01:29Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
656
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
656
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.3K
01:16Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K